Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) shares, rose in value, with the stock price down by -1.22% to the previous day’s close as strong demand from buyers drove the stock to $507.33.
Actively observing the price movement in the recent trading, the stock is buoying the session at $513.58, falling within a range of $506.38 and $521.05. The value of beta (5-year monthly) is 0.307 whereas the PE ratio is 12.91 over 12-month period. Referring to stock’s 52-week performance, its high was $1211.20, and the low was $476.49. On the whole, REGN has fluctuated by -17.48% over the past month.
With the market capitalization of Regeneron Pharmaceuticals, Inc currently standing at about $54.77 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Apr-29. The company’s Forward Dividend Ratio is 1.76, with its dividend yield at 0.35%.
The stock’s technical analysis shows that the PEG ratio is about 9.50, with the price of REGN currently trading nearly -4.09% and -9.16% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.56, while the 7-day volatility ratio is showing 1.91% which for the 30-day chart, stands at 5.09%. Furthermore, Regeneron Pharmaceuticals, Inc (REGN)’s beta value is 0.31, and its average true range (ATR) is 20.07.
A comparison of Regeneron Pharmaceuticals, Inc (REGN) with its peers suggests the former has fared considerably weaker in the market. REGN showed an intraday change of -1.22% in today’s session so far, and over the past year, it shrunk by -51.47%%.
Data on historical trading for Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) indicates that the trading volumes over the past 10 days have averaged 1.23 and over the past 3 months, they’ve averaged 1.33 million. According to company’s latest data on outstanding shares, there are 106.40 million shares outstanding.
Nearly 3.61% of Regeneron Pharmaceuticals, Inc’s shares belong to company insiders and institutional investors own 87.17% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.7 million shares as on 2025-05-30, resulting in a short ratio of 1.81. According to the data, the short interest in Regeneron Pharmaceuticals, Inc (REGN) stood at 264.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 2.89 million. The stock has fallen by -28.78% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the REGN stock heading into the next quarter.
